WithdrawnNot Applicable

Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder

Stopped: Study stopped after ethical approval but before first patient gave consent due to pandemic

United Kingdom0Started 2021-09-01

Plain-language summary

We hypothesise that a real-time quaking induced conversion assay for the detection of pathological alpha-synuclein (α -syn RTQuIC) can be used to differentiate between cases of idiopathic REM-sleep behaviour disorder (RBD) and RBD that is symptomatic of prodromal α-synucleinopathies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with Rapid Eye Movement Behaviour Disorder (RBD) using the International Classification of Sleep Disorders version 3 (ICSD-3) criteria \[18\] - Patients aged 18 years and over - Patient able to give written informed consent Exclusion Criteria: * RBD secondary to medication or withdrawal state. - \<18 years old - Inability to give written informed consent - Contraindication to lumbar puncture procedure (e.g. patients taking Warfarin)

What they're measuring

Presence of pathological α-synuclein within the cerebrospinal fluid (CSF)

Timeframe: 0-24 months after sample taken

Trial details

NCT IDNCT04266457

SponsorUniversity of Edinburgh

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-09-01

View on ClinicalTrials.gov More Sleep Disorder Rem Sleep Behavior trials